By Josh Beckerman

Turn Therapeutics shares were higher after the company reported favorable interim results from an eczema study with its lead drug candidate, GX-03.

The stock rose 28% to $6.65 Monday and is up about 69% this year.

Turn Therapeutics reported findings from the first 50 completed subjects enrolled in the Phase 2 clinical trial.

Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within four weeks compared to 65.2% for vehicle-treated subjects, the company said. GX-03 continued to demonstrate a favorable safety and tolerability profile.

"What became increasingly apparent during the interim review was the speed with which responses emerged," the company said. It said "The consistency of response across earlier efficacy measures suggests clinically meaningful improvement may emerge sooner than originally anticipated, which could have important implications for both future regulatory strategy and patient outcomes."

The company said it is preparing to initiate Food and Drug Administration interactions, including a meeting to discuss the evolving regulatory strategy for GX-03 and potential pathways for advancement.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 01, 2026 14:30 ET (18:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.